Abstract
Donepezil is a reversible, non-competitive piperidine-type acetylcholinesterase inhibitor (AChEI) that is structurally unique compared with other currently available AChEIs. It was developed as a symptomatic treatment to compensate for the progressive loss of cholinergic signal between neurons, a consequence of neuronal cell loss in the brains of patients with Alzheimer’s disease (AD). Clinical trials conducted over the 15 years since the drug was first licensed and available for use in patients with mild to moderate AD (1997) have shown that donepezil is efficacious and well tolerated at all stages of AD, from patients with mild or moderate impairment to those with severe disease. The published literature contains nearly 2000 papers on donepezil, and more than 200 of these articles relate to randomized controlled clinical trials. Trials in patients with mild cognitive impairment (MCI) failed to meet all of their primary objectives, but provided insights into patient selection and the design of trials. Overall, more than a decade of donepezil research has gradually changed attitudes toward therapy of AD from a general belief that no clinically useful treatment exists to the present day understanding that symptomatic therapy may be effective across the spectrum of dementia stages.
Keywords: Acetylcholinesterase inhibitor, Alzheimer’s disease, donepezil, mild cognitive impairment, mild to moderate Alzheimer’s disease, moderate severe to severe Alzheimer’s disease, neurodegenerative disease, cholinergic system, amyloid plaques, Dementia.
Current Alzheimer Research
Title:Reviewing the Role of Donepezil in the Treatment of Alzheimer’s Disease
Volume: 9 Issue: 7
Author(s): Rachelle S. Doody, Jeffrey L. Cummings and Martin R. Farlow
Affiliation:
Keywords: Acetylcholinesterase inhibitor, Alzheimer’s disease, donepezil, mild cognitive impairment, mild to moderate Alzheimer’s disease, moderate severe to severe Alzheimer’s disease, neurodegenerative disease, cholinergic system, amyloid plaques, Dementia.
Abstract: Donepezil is a reversible, non-competitive piperidine-type acetylcholinesterase inhibitor (AChEI) that is structurally unique compared with other currently available AChEIs. It was developed as a symptomatic treatment to compensate for the progressive loss of cholinergic signal between neurons, a consequence of neuronal cell loss in the brains of patients with Alzheimer’s disease (AD). Clinical trials conducted over the 15 years since the drug was first licensed and available for use in patients with mild to moderate AD (1997) have shown that donepezil is efficacious and well tolerated at all stages of AD, from patients with mild or moderate impairment to those with severe disease. The published literature contains nearly 2000 papers on donepezil, and more than 200 of these articles relate to randomized controlled clinical trials. Trials in patients with mild cognitive impairment (MCI) failed to meet all of their primary objectives, but provided insights into patient selection and the design of trials. Overall, more than a decade of donepezil research has gradually changed attitudes toward therapy of AD from a general belief that no clinically useful treatment exists to the present day understanding that symptomatic therapy may be effective across the spectrum of dementia stages.
Export Options
About this article
Cite this article as:
S. Doody Rachelle, L. Cummings Jeffrey and R. Farlow Martin, Reviewing the Role of Donepezil in the Treatment of Alzheimer’s Disease, Current Alzheimer Research 2012; 9 (7) . https://dx.doi.org/10.2174/156720512802455412
DOI https://dx.doi.org/10.2174/156720512802455412 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
Call for Papers in Thematic Issues
New Advances in the Prevention, Diagnosis, Treatment, and Rehabilitation of Alzheimer's Disease
Aims and Scope: Introduction: Alzheimer's disease (AD) poses a significant global health challenge, with an increasing prevalence that demands concerted efforts to advance our understanding and strategies for prevention, diagnosis, treatment, and rehabilitation. This thematic issue aims to bring together cutting-edge research and innovative approaches from multidisciplinary perspectives to address ...read more
Current updates on the Role of Neuroinflammation in Neurodegenerative Disorders
Neuroinflammation is an invariable hallmark of chronic and acute neurodegenerative disorders and has long been considered a potential drug target for Alzheimer?s disease (AD) and dementia. Significant evidence of inflammatory processes as a feature of AD is provided by the presence of inflammatory markers in plasma, CSF and postmortem brain ...read more
Deep Learning for Advancing Alzheimer's Disease Research
Alzheimer's disease (AD) poses a significant global health challenge, with an increasing number of individuals affected yearly. Deep learning, a subfield of artificial intelligence, has shown immense potential in various domains, including healthcare. This thematic issue of Current Alzheimer Research explores the application of deep learning techniques in advancing our ...read more
Diagnostic and therapeutic biomarkers of dementia
Dementia affects 18 million people worldwide. Dementia is a syndrome of symptoms caused by brain disease, usually chronic or progressive, clinically characterized by multiple impairments of higher cortical functions such as memory, thinking, orientation, and learning. In addition, in the course of dementia, cognitive deficits are observed, which often hinder ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Scutellarin Attenuates Microglia-Mediated Neuroinflammation and Promotes Astrogliosis in Cerebral Ischemia - A Therapeutic Consideration
Current Medicinal Chemistry Patterns of Cognitive Decline and Rates of Conversion to Dementia in Patients with Degenerative and Vascular forms of MCI
Current Alzheimer Research The Stress Rheostat: An Interplay Between the Unfolded Protein Response (UPR) and Autophagy in Neurodegeneration
Current Molecular Medicine Magnetic Resonance Imaging in Alzheimer’s Disease: from Diagnosis to Monitoring Treatment Effect
Current Alzheimer Research Experience and Perspectives of Caregivers of Spouse with Mild Cognitive Impairment
Current Alzheimer Research Commentary [Research Highlights : Neurotrophic Factor Treatment of Neurological Disorders: The Benefits of a Pleiotropic Treatment Approach]
CNS & Neurological Disorders - Drug Targets Diet and Neurocognition: Review of Evidence and Methodological Considerations
Current Aging Science Nuclear Medicine: Proof of Principle for Targeted Drugs in Diagnosis and Therapy
Current Pharmaceutical Design Hypertension Impairs Cerebral Blood Flow in a Mouse Model for Alzheimer’s Disease
Current Alzheimer Research Late-life Depression and Alzheimer Disease: A Potential Synergy of the Underlying Mechanisms
Current Medicinal Chemistry Meta-Analysis of the Effectiveness and Safety of Prophylactic Use of Nimodipine in Patients with an Aneurysmal Subarachnoid Haemorrhage
CNS & Neurological Disorders - Drug Targets Targeting α7 Nicotinic Acetylcholine Receptors in the Treatment of Schizophrenia
Current Pharmaceutical Design Review of Vital Signs Monitoring Systems – Patient’s Acceptability, Issues and Challenges
Neuroscience and Biomedical Engineering (Discontinued) Mitochondria: A Target for Neuroprotective Interventions in Cerebral Ischemia-Reperfusion
Current Pharmaceutical Design Neurotoxicity of Insecticides
Current Medicinal Chemistry Alterations in Glucose Metabolism on Cognition: A Possible Link Between Diabetes and Dementia
Current Pharmaceutical Design Pharmacological Countermeasures for the Acute Radiation Syndrome
Current Molecular Pharmacology Effects of Olive Oil on TNF-α and IL-6 in Humans: Implication in Obesity and Frailty
Endocrine, Metabolic & Immune Disorders - Drug Targets Impact of Hyperhomocyst(e)inemia on Endothelial Function
Vascular Disease Prevention (Discontinued) Visualization of Brain Amyloid and Microglial Activation in Mouse Models of Alzheimers Disease
Current Alzheimer Research